Twist Bioscience (NASDAQ:TWST) Posts Quarterly Earnings Results, Misses Expectations By $0.05 EPS

Twist Bioscience (NASDAQ:TWST) issued its earnings results on Friday. The company reported ($0.45) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.40) by ($0.05), FiscalAI reports. The firm had revenue of $99.01 million during the quarter, compared to analysts’ expectations of $97.40 million. Twist Bioscience had a negative return on equity of 29.03% and a negative net margin of 23.51%. Twist Bioscience updated its Q1 2026 guidance to EPS and its FY 2026 guidance to EPS.

Twist Bioscience Trading Down 10.1%

Shares of TWST stock traded down $3.03 on Friday, reaching $26.87. 5,757,640 shares of the stock were exchanged, compared to its average volume of 1,557,494. The company has a quick ratio of 3.60, a current ratio of 3.90 and a debt-to-equity ratio of 0.03. The stock has a market cap of $1.62 billion, a P/E ratio of -18.53 and a beta of 2.43. The firm has a 50 day moving average of $29.74 and a two-hundred day moving average of $31.40. Twist Bioscience has a 1-year low of $23.30 and a 1-year high of $55.33.

Insider Activity at Twist Bioscience

In other news, CEO Emily M. Leproust sold 4,887 shares of Twist Bioscience stock in a transaction dated Monday, November 3rd. The stock was sold at an average price of $32.08, for a total transaction of $156,774.96. Following the sale, the chief executive officer directly owned 733,922 shares of the company’s stock, valued at approximately $23,544,217.76. The trade was a 0.66% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, SVP Paula Green sold 1,084 shares of the stock in a transaction that occurred on Monday, November 3rd. The shares were sold at an average price of $32.08, for a total value of $34,774.72. Following the transaction, the senior vice president owned 142,187 shares of the company’s stock, valued at approximately $4,561,358.96. This trade represents a 0.76% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold a total of 122,865 shares of company stock valued at $3,879,926 over the last three months. Insiders own 3.01% of the company’s stock.

Hedge Funds Weigh In On Twist Bioscience

Large investors have recently modified their holdings of the stock. Goldman Sachs Group Inc. increased its holdings in Twist Bioscience by 4.2% in the first quarter. Goldman Sachs Group Inc. now owns 932,978 shares of the company’s stock valued at $36,629,000 after buying an additional 37,577 shares during the last quarter. Dimensional Fund Advisors LP lifted its position in shares of Twist Bioscience by 8.6% in the 3rd quarter. Dimensional Fund Advisors LP now owns 790,893 shares of the company’s stock worth $22,252,000 after buying an additional 62,300 shares during the last quarter. Bank of America Corp DE grew its holdings in shares of Twist Bioscience by 143.4% during the second quarter. Bank of America Corp DE now owns 688,332 shares of the company’s stock valued at $25,324,000 after purchasing an additional 405,560 shares during the last quarter. Balyasny Asset Management L.P. grew its stake in Twist Bioscience by 934.0% during the 2nd quarter. Balyasny Asset Management L.P. now owns 628,241 shares of the company’s stock worth $23,113,000 after buying an additional 567,481 shares during the last quarter. Finally, UBS Group AG increased its holdings in shares of Twist Bioscience by 137.7% in the 3rd quarter. UBS Group AG now owns 514,928 shares of the company’s stock worth $14,490,000 after acquiring an additional 298,331 shares during the period.

Analysts Set New Price Targets

A number of equities research analysts recently issued reports on TWST shares. Stephens started coverage on shares of Twist Bioscience in a research note on Monday, November 3rd. They issued an “overweight” rating and a $41.00 price target on the stock. Barclays cut their target price on Twist Bioscience from $45.00 to $40.00 and set an “overweight” rating for the company in a research note on Thursday, October 2nd. Weiss Ratings reiterated a “sell (e+)” rating on shares of Twist Bioscience in a research report on Thursday. Evercore ISI decreased their price objective on shares of Twist Bioscience from $46.00 to $42.00 and set an “outperform” rating on the stock in a report on Tuesday, October 7th. Finally, Cowen reaffirmed a “buy” rating on shares of Twist Bioscience in a research report on Monday, August 4th. Ten equities research analysts have rated the stock with a Buy rating and two have issued a Sell rating to the company. According to MarketBeat.com, Twist Bioscience currently has an average rating of “Moderate Buy” and a consensus target price of $47.80.

Twist Bioscience Company Profile

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.